Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Critical Care

ICU Advocacy: Fighting for Your Loved One

At a Glance

Survival of Primary Amebic Meningoencephalitis (PAM) requires immediate, aggressive intervention. Critical steps include securing the drug Miltefosine, implementing therapeutic hypothermia, utilizing an external ventricular drain for brain swelling, and consulting the CDC emergency team.

Navigating the ICU when your loved one is fighting Primary Amebic Meningoencephalitis (PAM) is a battle against time. While the fatality rate for this condition is extremely high (over 97%), the rare cases of survival provide a clear roadmap for advocacy [1][2]. In almost every instance where a patient survived, success was credited to early diagnosis and aggressive, multi-modal intervention [3][4][5].

As a family member, your role as an advocate is to ensure that the medical team is moving with the maximum possible urgency and utilizing every tool available.

Aggressive Treatment Protocols

The most famous survivors of PAM, including those from the 2013 cases in the United States, shared three critical factors in their care [6][7]:

  1. Immediate Miltefosine: They received the drug Miltefosine very early in the course of the infection [6][8].
  2. Aggressive Swelling Management: Doctors used therapeutic hypothermia (cooling the body to 32°C–34°C) to protect the brain and reduce swelling [6][9].
  3. Pressure Relief: Invasive monitoring, such as an External Ventricular Drain (EVD), was used to manage intracranial pressure (ICP) in real-time [6][10].

Actionable Advocacy Steps

You can help the clinical team by staying focused on these high-impact priorities:

1. Demand the Right Spinal Tap Protocol

If the doctors are preparing to do a lumbar puncture (spinal tap), you must specifically ask them before the procedure:

  • “Please ensure the CSF sample is not refrigerated, and have the lab immediately perform a warm ‘wet mount’ to check for motile amebae.” [11][2]. Standard labs refrigerate samples automatically, which stops the ameba from moving and hides it from the pathologist.

2. Confirm CDC Consultation

The CDC maintains a 24/7 emergency consultation service for PAM. Ensure your doctors have called the CDC Emergency Operations Center (770-488-7100) [12][13]. The CDC provides expert guidance on dosing and can help confirm the diagnosis through rapid molecular testing [14][6].

3. Secure Miltefosine Immediately

Miltefosine (Impavido) is a specialized drug and is not stocked in every hospital pharmacy.

  • The Logistical Race: If the hospital does not have it, they must locate the nearest supply immediately. You or the doctors can check the live map on the manufacturer’s (Profounda) website to find the nearest stocking hospital [14][6].
  • Push for Speed: Ask specifically, “Where is the Miltefosine coming from, and what is the exact estimated time of arrival?” [14].

4. Ask About Neuro-Protective Measures

Since brain swelling is a primary cause of death in PAM, managing it is as important as killing the ameba [10][9].

  • Targeted Temperature Management: Ask if the team is using therapeutic hypothermia to slow brain metabolism and reduce inflammation [9][15].
  • ICP Monitoring: Ask how they are measuring the pressure inside the skull and if an EVD or “shunt” is necessary to drain excess fluid [16][17].

Maintaining the Urgency

PAM is a fulminant (rapidly progressive) disease [18]. In the ICU, “waiting and seeing” is never an option for this specific infection. Your goal is to keep the conversation focused on immediate, aggressive action. If the medical team is hesitant because the diagnosis is not yet 100% confirmed, remind them that in survival cases, treatment often started based on suspicion rather than waiting for every test result [19][20][15].

Common questions in this guide

Why must the spinal tap fluid stay warm during PAM testing?
Refrigerating the cerebrospinal fluid stops the amoeba from moving. To properly identify Naegleria fowleri, the lab must perform a warm wet mount so pathologists can actually see the moving amebae under the microscope.
What is Miltefosine and why is it important for PAM?
Miltefosine is a specialized medication that has been critical in documented cases of PAM survival. Because it is not stocked in every hospital pharmacy, care teams often need to urgently locate it using the manufacturer's emergency supply map.
How is brain swelling managed in Primary Amebic Meningoencephalitis?
Because severe brain swelling is a primary cause of death in PAM, doctors often use therapeutic hypothermia to cool the body and reduce inflammation. They may also insert an External Ventricular Drain (EVD) to monitor and drain excess fluid to relieve pressure inside the skull.
Can treatment for PAM begin before the diagnosis is fully confirmed?
Yes. Because PAM progresses so rapidly, aggressive treatment in survival cases frequently begins based on strong clinical suspicion rather than waiting for all specialized test results to return.
How can the CDC help with a suspected PAM case?
The CDC maintains a 24/7 emergency consultation service specifically for PAM. Their experts provide critical guidance to your medical team on multi-drug dosing and assist with rapid molecular testing to confirm the diagnosis.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have you spoken directly with the CDC’s Naegleria fowleri experts to review this specific case and confirm the dosing?
  2. 2.How quickly can we get Miltefosine here? If the hospital doesn't have it, can we locate the nearest emergency supply using the manufacturer's map?
  3. 3.Are we using therapeutic hypothermia (cooling the body) to manage brain swelling, as was done in several survival cases?
  4. 4.Given the rapid progression, should we consider an External Ventricular Drain (EVD) to monitor and relieve pressure in the brain?
  5. 5.Is the patient on the most aggressive multi-drug regimen possible right now, including intrathecal medications?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Naegleria fowleri: Portrait of a Cerebral Killer.

    Phung NTN, Pham HT, Tran TT, et al.

    Diagnostics (Basel, Switzerland) 2025; (15(1)) doi:10.3390/diagnostics15010089.

    PMID: 39795618
  2. 2

    Laboratory Diagnosis of Primary Amoebic Meningoencephalitis.

    Rojo JU, Rajendran R, Salazar JH

    Laboratory medicine 2023; (54(5)):e124-e132 doi:10.1093/labmed/lmac158.

    PMID: 36638160
  3. 3

    Primary Amebic Meningoencephalitis: What Have We Learned in the Last 5 Years?

    Cope JR, Ali IK

    Current infectious disease reports 2016; (18(10)):31 doi:10.1007/s11908-016-0539-4.

    PMID: 27614893
  4. 4

    Epidemiology and Clinical Characteristics of Primary Amebic Meningoencephalitis Caused by Naegleria fowleri: A Global Review.

    Gharpure R, Bliton J, Goodman A, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2021; (73(1)):e19-e27 doi:10.1093/cid/ciaa520.

    PMID: 32369575
  5. 5

    Amebic encephalitis and meningoencephalitis: an update on epidemiology, diagnostic methods, and treatment.

    Haston JC, Cope JR

    Current opinion in infectious diseases 2023; (36(3)):186-191 doi:10.1097/QCO.0000000000000923.

    PMID: 37093056
  6. 6

    Naegleria fowleri: Diagnosis, Pathophysiology of Brain Inflammation, and Antimicrobial Treatments.

    Pugh JJ, Levy RA

    ACS chemical neuroscience 2016; (7(9)):1178-9 doi:10.1021/acschemneuro.6b00232.

    PMID: 27525348
  7. 7

    Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis.

    Linam WM, Ahmed M, Cope JR, et al.

    Pediatrics 2015; (135(3)):e744-8 doi:10.1542/peds.2014-2292.

    PMID: 25667249
  8. 8

    Surviving Naegleria fowleri infections: A successful case report and novel therapeutic approach.

    Heggie TW, Küpper T

    Travel medicine and infectious disease 2017; (16()):49-51 doi:10.1016/j.tmaid.2016.12.005.

    PMID: 28013053
  9. 9

    A local case of fulminant primary amoebic meningoencephalitis due to Naegleria fowleri.

    McLaughlin A, O'Gorman T

    Rural and remote health 2019; (19(2)):4313 doi:10.22605/RRH4313.

    PMID: 30961348
  10. 10

    Primary amebic meningoencephalitis in children: A case report and literature review.

    Song B, Zheng J, Zhao D

    IDCases 2024; (37()):e02028 doi:10.1016/j.idcr.2024.e02028.

    PMID: 39109186
  11. 11

    Challenges and Strategies in Managing Naegleria fowleri-Associated Primary Amoebic Meningoencephalitis in Pakistan: A Case Report.

    Zaman M, Fida T, Haris HM, et al.

    Acta parasitologica 2025; (70(4)):150 doi:10.1007/s11686-025-01091-2.

    PMID: 40622499
  12. 12

    Advancing the understanding of Naegleria fowleri: Global epidemiology, phylogenetic analysis, and strategies to combat a deadly pathogen.

    Alanazi A, Younas S, Ejaz H, et al.

    Journal of infection and public health 2025; (18(4)):102690 doi:10.1016/j.jiph.2025.102690.

    PMID: 39913985
  13. 13

    A case report: primary amoebic meningoencephalitis in a young Zambian adult.

    Chomba M, Mucheleng'anga LA, Fwoloshi S, et al.

    BMC infectious diseases 2017; (17(1)):532 doi:10.1186/s12879-017-2638-8.

    PMID: 28764655
  14. 14

    Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case.

    Cope JR, Conrad DA, Cohen N, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; (62(6)):774-6 doi:10.1093/cid/civ1021.

    PMID: 26679626
  15. 15

    Successful Treatment of Confirmed Naegleria fowleri Primary Amebic Meningoencephalitis.

    Burqi AMK, Satti L, Mahboob S, et al.

    Emerging infectious diseases 2024; (30(4)):803-805 doi:10.3201/eid3004.230979.

    PMID: 38526236
  16. 16

    Timing of neurosurgical interventions for intracranial hypertension: the intensivists' and neurosurgeons' view.

    Lin V, Hutchinson PJ, Kolias A, et al.

    Current opinion in critical care 2025; (31(2)):137-148 doi:10.1097/MCC.0000000000001243.

    PMID: 39991845
  17. 17

    External ventricular drainage for intracranial hypertension after traumatic brain injury: is it really useful?

    Moyer JD, Elouahmani S, Codorniu A, et al.

    European journal of trauma and emergency surgery : official publication of the European Trauma Society 2023; (49(3)):1227-1234 doi:10.1007/s00068-022-01903-4.

    PMID: 35169869
  18. 18

    The Brief Case: A Case of Primary Amebic Meningoencephalitis (PAM) after Exposure at a Splash Pad.

    Eger L, Pence MA

    Journal of clinical microbiology 2023; (61(7)):e0126922 doi:10.1128/jcm.01269-22.

    PMID: 37470480
  19. 19

    Killer amoebas: Primary amoebic meningoencephalitis in a changing climate.

    Cooper AM, Aouthmany S, Shah K, Rega PP

    JAAPA : official journal of the American Academy of Physician Assistants 2019; (32(6)):30-35 doi:10.1097/01.JAA.0000558238.99250.4a.

    PMID: 31136398
  20. 20

    Primary amoebic meningoencephalitis in children- report of two cases from South India.

    Joseph RB, Rauf A, Chettali AM, et al.

    Tropical doctor 2022; (52(4)):553-555 doi:10.1177/00494755221097046.

    PMID: 35880290

This page provides educational information on ICU advocacy for PAM and does not replace professional medical advice. Because this is a life-threatening emergency, always defer to the CDC and your loved one's critical care team for medical decisions.

Get notified when new evidence is published on Primary amebic meningoencephalitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.